GLA
APRE icon

Great Lakes Advisors’s Aprea Therapeutics APRE Stock Holding History

Great Lakes Advisors’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-895
Closed -$87K – 693
2021
Q2 		$87K Buy
+895
New +$82.7K ﹤0.01% 691

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Great Lakes Advisors's APRE Position: Q3 2021 in Review

Great Lakes Advisors sold out of Aprea Therapeutics (APRE) in Q3 2021, closing a stake of 895 shares — an estimated $87K sold.

Great Lakes Advisors first reported a position in APRE in Q2 2021 and held it in 1 quarter. The position peaked at $87K in Q2 2021. 39 funds tracked by Wall St. Rank hold APRE as of Q3 2021.

  • Great Lakes Advisors reported no remaining Aprea Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Great Lakes Advisors sold 895 Aprea Therapeutics shares in Q3 2021, an estimated $87K.
  • Great Lakes Advisors first reported a position in Aprea Therapeutics in Q2 2021 and held it in 1 quarter.
  • Great Lakes Advisors's Aprea Therapeutics position peaked at $87K in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2021.

Based on Great Lakes Advisors's 13F filing for Q3 2021, filed 9 Nov 2021.